

Company Overview

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders—with the hope of helping people overcome their disease and live a better life. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Kezar is translating its innovative research in protein degradation (via immunoproteasome inhibition) and protein secretion (via the Sec61 translocon) to have a significant clinical impact in the most difficult-to-treat diseases. KZR-616, our selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from our protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Sep 2 2021, 7:00 AM EDT

Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

Aug 23 2021, 7:01 AM EDT

Kezar Life Sciences Reports Second Quarter Financial Results and Provides Business Updates

Aug 12 2021, 4:02 PM EDT

Stock Overview

Symbol	KZR
Exchange	Nasdaq
Market Cap	468.92m
Last Price	\$9.73
52-Week Range	\$4.34 - \$9.41

09/17/2021 04:00 PM EDT

Investor Relations

Michael Wolfe
IR@kezarbio.com

Management Team

John Fowler

Chief Executive Officer, Co-Founder

Christopher Kirk, Ph.D.

President and Chief Scientific Officer, Co-Founder

Noreen Roth Henig, M.D.

Chief Medical Officer

Marc Belsky

Chief Financial Officer

Mark Schiller

Vice President, Legal Affairs

Michael Wolfe

Vice President, Finance and Business Operations

Kezar Life Sciences, Inc.

4000 Shoreline Court
Suite 300
South San Francisco, CA 94080

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.